Wednesday, July 8, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Clinical program

TAK-007

Phase 1 · mab · Refractory Lupus Nephritis

TAK-007 for Refractory Lupus Nephritis is a Phase 1 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).

← All Takeda projects Phase 1 mab terminated

Internal code TAK-007-1001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Takeda
Phase
Phase 1
Modality
mab
Indication
Refractory Lupus Nephritis
Status
terminated
Trials
1

Clinical trials